Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Opinion|Podcasts|January 29, 2025
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Advertisement
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
In situ immunotherapy shows encouraging survival findings in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5